At a glance
- Originator ADIR
- Developer Servier
- Class Antihyperlipidaemics
- Mechanism of Action Lipid peroxidation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 29 Aug 2006 Discontinued - Preclinical for Atherosclerosis in France (unspecified route)
- 10 Nov 1994 Preclinical development for Atherosclerosis in France (Unknown route)